-transparent.png){kind=logo}
Twenty-six patients affected by Parkinson's disease were treated with a 2-Br-alpha-ergocriptine (CB 154): 14 cases were given CB 154 alone, and 12 were given CB 154 along with L-dopa plus benserazide (Madopar). Both CB 154 and combined therapy (CB 154+Madopar) induced a significant improvement in total disability score, tremor, rigidity, akinesia, self-sufficiency, and some motor performance tests (dynamic tests). No significant difference was found between results obtained with CB 154 therapy and with Madopar treatment, while the improvement induced by combined therapy (CB 154+Madopar) was significantly higher than that obtained by Madopar alone. The averse reactions caused by CB 154 alone or associated with Madopar are similar to those observed during other dopaminergic treatment. CB 154 alone or combined with Madopar appears to be a useful advance in the management of Parkinson's disease.
T A Caraceni, and
I Celano, and
E Parati, and
F Girotti
January 1990,
European neurology,
T A Caraceni, and
I Celano, and
E Parati, and
F Girotti
May 1979,
Wiener klinische Wochenschrift,
T A Caraceni, and
I Celano, and
E Parati, and
F Girotti
January 1974,
Rivista di neurologia,
T A Caraceni, and
I Celano, and
E Parati, and
F Girotti
January 1995,
Annals of neurology,
T A Caraceni, and
I Celano, and
E Parati, and
F Girotti
January 1972,
Revue canadienne de biologie,
T A Caraceni, and
I Celano, and
E Parati, and
F Girotti
April 1979,
No to shinkei = Brain and nerve,
T A Caraceni, and
I Celano, and
E Parati, and
F Girotti
March 1979,
No to shinkei = Brain and nerve,
T A Caraceni, and
I Celano, and
E Parati, and
F Girotti
January 1972,
Zeitschrift fur Neurologie,
T A Caraceni, and
I Celano, and
E Parati, and
F Girotti
January 1991,
Medicina,
T A Caraceni, and
I Celano, and
E Parati, and
F Girotti
July 1986,
The British journal of clinical practice,
